Pharmaceutical

FDA expands approval of Dupixent for eosinophilic esophagitis in children

Regeneron and Sanofi’s blockbuster anti-inflammatory drug generated global sales of $8.68bn in 2022.

Jan 27, 2024 - 18:00
FDA expands approval of Dupixent for eosinophilic esophagitis in children
Regeneron and Sanofi’s blockbuster anti-inflammatory drug generated global sales of $8.68bn in 2022.
Read the original article

Tags:

Previous Article

Atossa Therapeutics progresses Phase II preventative breast cancer therapy

Next Article

Travere signs $120m licensing deal with Renalys for sparsentan in Asia

What's Your Reaction?

like

dislike

love

funny

angry

sad

wow

Related Posts

Magenta Therapeutics and Dianthus agree to merge operations

Magenta Therapeutics and Dianthus agree to merge operat...

May 4, 2023

Anti-RANKL Monoclonal Antibody by Jiangsu Pacific Meinuoke Bio-Pharmarceutical for Osteoporosis: Likelihood of Approval

Anti-RANKL Monoclonal Antibody by Jiangsu Pacific Meinu...

Jun 20, 2024

STAT+: Apple Watch pulse oximeter feature removed to comply with ban

STAT+: Apple Watch pulse oximeter feature removed to co...

Jan 18, 2024